Companies join forces to speed production of 1-time treatment for FSHD
WHY IT MATTERS
This partnership could accelerate production of EPI-321, potentially bringing a one-time treatment option closer to FSHD patients who currently have limited approved therapies.
Two companies, Epicrispr Biotechnologies and Forge Biologics, are working together to make EPI-321, a new one-time treatment for facioscapulohumeral muscular dystrophy (FSHD). FSHD is a rare muscle disease that causes progressive weakness. The treatment works by using epigenetics—a way to turn off genes without changing their DNA—to stop the abnormal gene that causes FSHD.
Epicrispr Biotechnologies is partnering with Forge Biologics to support the development of EPI-321, Epicrispr’s one-time epigenetic treatment candidate for facioscapulohumeral muscular dystrophy (FSHD). The treatment uses epigenetics — chemical modifications that can alter gene activity without changing a gene’s DNA sequence — to turn off the abnormally-activated gene that underlies FSHD. According to the developer, […] The post Companies join forces to speed production of 1-time treatment